Anorexia and cachexia are frequent complications of both HIV infection
and cancer. Involuntary weight loss and associated malnutrition
result in physical and psychological consequences that affect
both morbidity and mortality. Numerous investigators have reported
on the relationship between involuntary weight loss and adverse
outcome in the setting of HIV infection or cancer. Malnutrition
adversely affects immune function, increases the risk of infection,
and diminishes tolerance to radiation therapy, response to chemotherapy,
and overall survival .
Whether nutritional status is evaluated using simple clinical
nutritional markers, such as serum albumin and percentage of usual
body weight, or by sophisticated research techniques, the deleterious
effects of malnutrition on the clinical course of HIV infection
are well documented. Indeed, malnutrition is a predictor of both
risk of hospitalization and survival . Regardless of the clinical
setting, death from wasting is directly related to the magnitude
of tissue depletion, suggesting that the preservation and/or restoration
of body cell mass may enhance survival .
The pathogenesis of wasting is incompletely defined. However,
it appears to result from complex interactions among decreased
energy intake, altered energy expenditure, malabsorption, and
hormonal/cytokine and metabolic abnormalities. The respective
roles of individual factors, such as altered insulin sensitivity,
hypertriglyceridemia, futile cycling of glucose and/or free fatty
acids, hypermetabolism or hypometabolism, and alterations in the
cytokine milieu, are difficult to identify. Ultimately, weight
loss is determined by the balance between energy intake and energy
expenditure. Increasingly, data suggest reduced energy intake
as the major determinant of involuntary weight loss in patients
with HIV infection, and, to a less degree, in those with cancer
Anorexia is a frequent clinical complaint of patients with malignant
disease or HIV infection. Bruera, in a review of 275 consecutive
cancer patients admitted to a palliative care unit, noted anorexia
to be present in 85% of patients, second in frequency only to
the complaint of asthenia and more common than complaints of cancer-related
Similarly, anorexia is a highly prevalent symptom in the setting
of HIV infection, although its exact prevalence is unknown. In
a review of clinical risk factors for malnutrition in 104 HIV-infected
patients (including asymptomatic patients, as well as those with
AIDS or AIDS-related complex [ARC]), anorexia was identified as
the predominant risk factor in 60% of patients . Furthermore,
Burger et al reported the benefit of intensified oral nutritional
intervention in malnourished HIV-infected outpatients, suggesting
that poor spontaneous nutrient intake is an important pathogenetic
factor in the development of HIV-related malnutrition .
In patients with HIV infection, the degree of weight loss has
been closely associated with reduced energy intake. McCorkindale
et al noted a correlation between weight loss and decreased oral
intake over a 16-month period in asymptomatic patients with HIV
infection or early ARC . In an evaluation by Grunfeld et al
comparing metabolic parameters and oral intake in HIV-seropositive
subjects, seronegative controls, and AIDS patients with and without
active secondary infections, a highly significant correlation
between 28-day weight loss and caloric intake was identified,
while no correlation was seen between resting energy expenditure
and weight loss . Similarly, Macallan et al found reduced energy
intake, not elevated energy expenditure, to be the primary determinant
of weight loss in 27 HIV-seropositive men at different stages
of the disease .
Although weight loss appears to be progressive over the course
of HIV infection, it does not occur continuously. Rather, weight
is more often lost in a stepwise fashion in association with opportunistic
complications of the underlying immunosuppression. This episodic
weight loss is associated with decreased oral intake, which, during
its early stages, may be amenable to therapeutic intervention.
Although not all investigators agree, a number of studies suggest
that attention to oral intake by clinicians results in an improvement
in overall nutritional status. McKinley et al demonstrated improved
nutritional status in adult outpatients who received nutritional
assessment, counseling, and follow-up, compared with outpatients
who received no nutritional intervention . In contrast, Chleblowski
et al reported progressive weight loss in HIV-infected individuals
despite dietary counseling, suggesting the need for earlier intervention
and consideration of increased target levels for energy intake
The etiology of anorexia is incompletely understood.
The endogenous production of cytokines contributes to the development
of anorexia and cachexia in both HIV infection and advanced cancer.
Experimental therapy in vitro and in vivo with cytokines, such
as interferon, tumor necrosis factor (TNF), and interleukin-1
(IL-1), can produce striking anorexia [11-13]. Tumor necrosis
factor, although frequently cited as a major cause of anorexia,
is not consistently elevated in the serum of patients with cancer
cachexia or HIV-related wasting [11-14].
Although individual cytokines can result in significant anorexia
when given as single factors in the experimental setting, tolerance
to their anorexic effects generally develops and normal food intake
resumes . Synergism between cytokines (eg, IL-1 plus interferon-alfa
or TNF) may result in irreversible anorexia, metabolic abnormalities,
and progressive weight loss.
Food intake may be further decreased by readily identifiable,
often reversible causes.
Nausea and Vomiting--Chronic nausea is a frequent complaint
in patients with HIV infection or cancer. Nausea and vomiting
can occur as a result of mechanical obstruction, infectious complications,
or as a side effect of medications (see Tables 1 and 2).
In the setting of HIV infection, numerous medications are prescribed
both for prophylaxis and treatment of opportunistic infections
that, alone or in combination, may cause nausea and vomiting;
examples include sulfamethoxazole for the treatment of Pneumocystis
carinii pneumonia or clarithromycin (Biaxin) as therapy or
prophylaxis for Mycobacterium avium complex.
Nausea and vomiting occur as both an immediate and late effect
of treatment with chemotherapeutic drugs such as cisplatin (Platinol).
Radiation therapy, particularly when the treatment field includes
the gastrointestinal tract, may also cause significant nausea.
In patients with advanced disease, whether cancer or HIV infection,
a not infrequent cause of nausea and vomiting is a rapid increase
in the dose of narcotic analgesics. In patients receiving high
doses of narcotics, nausea may be severe, chronic, and accompanied
by other gastrointestinal symptoms, including abdominal pain,
constipation, and large bowel distention.
Psychosocial or Financial Factors--Decreased oral intake
may result from psychosocial or financial factors. Patients have
identified anxiety, depression, and/or a sense of isolation as
factors interfering with oral intake. Neuropsychiatric symptoms
associated with HIV infection and opportunistic pathogens of the
central nervous system or central nervous system metastases, including
dementia, sensory and motor abnormalities, and psychosis, also
may result in decreased caloric intake.
Mechanical impediments to food intake secondary to strictures
and/or progressive malignant disease further impair nutritional
status. Oral and esophageal conditions that result in dysphasia
and food aversions, such as esophageal candidiasis, aphthous stomatitis,
and therapy-induced mucositis, occur in patients with both cancer
and HIV infection. Cytomegaloviral or herpetic esophagitis are
most frequently seen in the severely immunocompromised host. Bulky
oropharyngeal Kaposi's sarcoma or other aerodigestive tract malignancies
may also make eating painful or unpleasant.
Early satiety may further compromise oral intake. Early
satiety may be secondary to ascites, hepatomegaly, or massive
splenomegaly (due to progressive malignancy or organ infiltration
by opportunistic infections [eg, cytomegalovirus or M avium
complex]). Abdominal fullness, regardless of the cause, has
been identified as one of the most important symptoms influencing
weight loss in patients with unresectable malignancy .
Diarrhea is the most common gastrointestinal tract symptom
in patients with HIV infection. It is often difficult to treat
and may become a major debilitating aspect of a patient's illness.
Not infrequently, diarrhea is associated with decreased oral intake,
perhaps because patients attempt to reduce fecal output by restricting
food intake, or because unabsorbed nutrients in the gastrointestinal
tract suppress appetite. Similarly, diarrhea is a prominent symptom
in patients with certain tumors, such as metastatic islet-cell
1. Bruera E: Is the pharmacological treatment of cancer cachexia
possible? Support Care
Cancer 1(6):298-304, 1993.
2. Cohan GR, Muurahainen N, Guenter P, et al: HIV-related hospitalization,
CD4 percent and nutritional markers (abstract 7113). Proceedings
of the VIII International Conference on AIDS, Amsterdam, June
1992, vol 3, p 67.
3. Kotler DP, Tierney AR, Wang J, et al: Magnitude of body-cell
mass depletion and the timing of death from wasting in AIDS. Am
J Clin Nutr 50:444-447, 1989b.
4. Macallan DC, Noble C, Baldwin C, et al: Energy expenditure
and wasting in human immunodeficiency virus infection. N Engl
J Med 333:83-88, 1995.
5. Grunfeld C, Pang M, Shimizu L, et al: Resting energy expenditure,
caloric intake, and short-term weight change in human immunodeficiency
virus infection and the acquired immunodeficiency syndrome.
Am J Clin Nutr 55:455-460, 1992.
6. Schwenk A, Bürger B, Wessel D, et al: Clinical risk factors
for malnutrition in HIV-1-infected patients. AIDS 7:1213-1219,
7. Burger B, Ollenschlager G, Schrappe M, et al: Nutrition behavior
of malnourished HIV-infected patients and intensified oral nutritional
intervention. Nutrition 9:43-44, 1993.
8. McCorkindale C, Dybevik K, Coulsten AM, et al: Nutritional
status of HIV-infected patients during the early disease stages.
J Am Diet Assoc 90:1236-1241, 1990.
9. McKinley MJ, Goodman-Block J, Sable AD: Improved nutritional
status as a result of nutrition intervention in adult HIV+ outpatients
(abstract PO-B36-2365). Proceedings of 9th International Conference
on AIDS, Berlin, vol 1.
10. Chlebowski RT, Grosvenor M, Lillington L, et al: Dietary intake
and counseling, weight maintenance, and the course of HIV infection.
J Am Diet Assoc 96(4):428-432, 1995.
11. Tracey KJ, Cerami A: Tumor necrosis factor: A pleiotropic
cytokine an therapeutic target. Annu Rev Med 45:491-503,
12. Hellerstein MK, Meydani SN, Meydani M, et al: CA: Interleukin-1
induced anorexia in the rat. J Clin Invest 84:228-235,
13. Spiegel RJ: The alpha interferons: Clinical overview. Semin
Oncol 14(2):1-12, 1987.
14. Grunfeld C, Kotler DP, Shigenago JK, et al: Circulating interferon-alpha
levels and hypertriglyceridemia in the acquired immunodeficiency
syndrome. Am J Med 90:154-162, 1991.
15. Grosvenor M, Bulcavage L, Chlebowski RT: Symptoms potentially
influencing weight loss in a cancer population. Cancer
16. Moertel C, Schulte A, Reitemeier R: Corticosteroid therapy
of preterminal gastrointestinal cancer. Cancer 33:1607-1609, 1974.
17. Wilcox J, Corr J, Shaw J: Prednisone as an appetite stimulant
in patients with cancer. Br Med J 200:37, 1984.
18. Bruera E, Roca E, Cedaro L: Action of oral methylprednisolone
in terminal cancer patients: A prospective randomized double-blind
study. Cancer Treat Rep 69:751-754, 1985.
19. Robustelli D, Cuna G, Pellegrini A, et al: Effect of methylprednisolone
sodium succinate on quality of life in pre-terminal cancer patients:
A placebo controlled, multi-center study. Eur J Cancer Clin
Oncol 25:1817-1821, 1989.
20. Popiela T, Lucchi R, Giongo F: Methylprednisolone as palliative
therapy for female terminal cancer patients. Eur J Cancer Clin
Oncol 25:1823-1829, 1989.
21. Kardinal C, Loprinzi C, Shaw P: A controlled trial of cyproheptadine
in cancer patients with anorexia. Cancer 65:2657-2662,
22. Filov VA, Danova LA, Gershanovich ML, et al: Results of clinical
evaluation of hydrazine sulfate. Voprosy Onkologii 36:721-726,
23. Hughes TK, Cadet P, Larned CS: Modulation of tumor necrosis
factor activities by a potential anticachexia compound, hydrazine
sulfate. Int J Immunopharmacol 11:501-507, 1989.
24. Kosty MP, Fleishman SB, Herndon JE II, et al: Cisplatin, vinblastine
and hydrazine sulfate in advanced non-small cell lung cancer:
A randomized placebo-controlled double blind phase III study of
the cancer and leukemia group. Br J Clin Oncol 12:1113-1120,
25. Loprinzi CL, Goldberg RM, Su JQ, et al: Placebo-controlled
trial of hydrazine sulfate in patients with newly diagnosed non-small-cell
lung cancer. J Clin Oncol 12:1126-1129, 1994.
26. Loprinzi CL, Kuross SA, O'Fallon JR, et al: Randomized placebo-controlled
evaluation of hydrazine sulfate in patients with advanced colorectal
cancer. J Clin Oncol 12(6):1121-1125, 1994.
27. Sallan SE, Cronin C, Zelen M, et al: Antiemetics in patients
receiving chemotherapy for cancer. N Engl J Med 302:135-138,
28. Wadleigh R, Spaulding M, Lembersky B, et al: Dronabinol enhancement
of appetite in cancer patients (abstract). Am Soc Clin Oncol
29. Nelson K, Walsh D, Decter P, et al: A phase II study of delta-9-tetrahydrocannabinol
for appetite stimulation in cancer-associated anorexia. J Palliat
Care 10:14-18, 1994.
30. Gorter R, Seefried M, Volberding P: Dronabinol effects on
weight in patients with HIV infection. AIDS 6:127-128, 1992.
31. Beal JE, Olson R, Laubenstein L, et al: Dronabinol as a treatment
for anorexia associated with weight loss in patients with AIDS.
J Pain Symptom Management 2:89-97, 1995.
32. Tchekmedyian NS, Tait N, Moody M, et al: High dose megestrol
acetate: A possible treatment for cachexia. JAMA 9:1195-1198,
33. Bruera E, MacMillan K, Kuehn N, et al: A controlled trial
of megestrol acetate on appetite, caloric intake, nutritional
status and other symptoms in patients with advanced cancer. Cancer
34. Loprinzi CL, Ellison NM, Schaid DJ, et al: Controlled trial
of megestrol acetate for the treatment of cancer anorexia and
cachexia. J Natl Cancer Inst 82:1127-1132, 1990.
35. Loprinzi CL, Schaid DJ, Dose AM, et al: Body composition changes
in patients who gain weight while receiving megestrol acetate.
J Clin Oncol 11:152-154, 1993.
36. Oster MH, Enders SR, Samuels SJ, et al: Megestrol acetate
in patients with AIDS and cachexia. Ann Intern Med 121:400-408,
37. Von Roenn JH, Armstrong D, Kotler DP, et al: Megestrol acetate
in patients with AIDS-related cachexia. Ann Intern Med
38. Engelson ES, Pi-Sunyer FX, Kotler DP: Effects of megestrol
acetate therapy on body composition and circulating testosterone
concentrations in patients with AIDS. AIDS 9:1107-1108, 1995.
39. Sallis JF, Haskill WL, Wood PD, et al: Physical activity assessment
methodology in the five-city project. Am J Epidemiol 121:91-106,
40. Solomon GF, Tomoshok LA: A psychoneuroimmunologic perspective
on AIDS research: Questions, preliminary findings and suggestions.
J Appl Soc Psychol 17:286-308, 1987.
41. Keyes C, Rodgers P, Wolbert J, et al: Effect of cardiovascular
conditioning in HIV infection. Proceedings of the 5th International
Conference on AIDS, Montreal, p 363, 1989.
42. Schlenzig C, Jager H, Rieder H, et al: Supervised physical
exercise leads to psychological and immunological improvements
in pre-AIDS patients. Proceedings of the 5th International
Conference on AIDS, Montreal, p 337, 1989.
43. MacArthur RD, Levine SD, Birk TJ: Supervised excercise training
improves cardiopulmonary fitness in HIV-infected persons. Medicine
and Science in Sports and Exercise, 25:684-688, 1993.
44. Johnson JE, Anders GT, Blanton HM, et al: Exercise dysfunction
in patients with the human immunodeficiency virus. Am Rev Respir
Dis 141:618-622, 1990.
45. Mulligan K, Grunfeld C, Hellerstein MK, et al: Anabolic effects
of recombinant human growth hormone in patients with wasting associated
with human immunodeficiency virus infection. J Clin Endocrinol
Metab 77:956-962, 1993.
46. Schambelan M, Grunfeld C, Mulligan K: Use of anabolic agents
in HIV infection
(abstract). Symposium on wasting disorders. Mol Clin Aspects,
47. Lieberman SA, Butterfield GE, Harrison D, et al: Anabolic
effects of recombinant insulin-like growth factor-1 in cachectic
patients with Acquired Immunodeficiency Syndrome. J Clin Endocrinol
Metab 78:404-410, 1994.
48. Rabkin JG, Rabkin R, Wagner G: Testosterone replacement therapy
in HIV illness.
General Hospital Psychiatry 17:37-42, 1995.
49. Jeantils V, Nguyen G, Bacle F, et al: Weight gain under oral
testosterone undecenoate in AIDS. Therapie 48:59-72, 1993.
50. Chlebowski RT, Herold J, Ali I, et al: Influence on nandrolone
decanoate on weight loss in advanced non-small cell lung cancer.
Cancer 58:183-186, 1986.
51. Dezube BJ, Fridovich-Keil JL, Bouvard I, et al: Pentoxifylline
and well-being in patients with cancer. Lancet 335-662,
52. Goldberg RM, Loprinzi CL, Mailliard JA, et al: pentoxifylline
for treatment of cancer anorexia and cachexia? A randomized, double-blind,
placebo-controlled trial. J Clin Oncol 13:2856-2859, 1995.